论文部分内容阅读
目的研究分析吉西他滨联合多西紫杉醇新辅助化疗方案在局部晚期肺癌中的临床效果。方法局部晚期肺癌患者97例,将其按照住院号尾号的奇偶分为治疗组(49例)和对照组(48例),治疗组患者采用吉西他滨联合多西紫杉醇新辅助化疗进行治疗,对照组患者采用多西紫杉醇治疗,对比两组患者临床治疗效果以及药物反应情况。结果治疗组患者总有效率为61.2%,对照组为39.6%,两组治疗效果比较差异具有统计学意义(P<0.05);两组患者临床用药不良反应主要为血小板减少、恶心呕吐以及白细胞减少等,发生率对比差异无统计学意义(P>0.05)。结论吉西他滨联合多西紫杉醇新辅助化疗方案在局部晚期肺癌可以提高患者的治疗效果,延长存活时间,可推广。
Objective To study the clinical effect of gemcitabine plus docetaxel neoadjuvant chemotherapy in locally advanced lung cancer. Methods Ninety-seven patients with locally advanced lung cancer were divided into the treatment group (49 cases) and the control group (48 cases) according to the odd-even number of tail number. The patients in the treatment group were treated with gemcitabine and docetaxel neoadjuvant chemotherapy. The control group Patients were treated with docetaxel, compared the clinical efficacy of two groups of patients and drug reactions. Results The total effective rate was 61.2% in the treatment group and 39.6% in the control group, the difference between the two groups was statistically significant (P <0.05). The clinical adverse reactions in the two groups were mainly thrombocytopenia, nausea and vomiting and leukopenia There was no significant difference in incidence between the two groups (P> 0.05). Conclusion Gemcitabine combined with docetaxel neoadjuvant chemotherapy regimen in patients with advanced lung cancer can improve the therapeutic effect, prolong survival and can be extended.